NasdaqCM - Delayed Quote USD

Fennec Pharmaceuticals Inc. (FENC)

9.24 -0.14 (-1.49%)
At close: 4:00 PM EDT
Loading Chart for FENC
DELL
  • Previous Close 9.38
  • Open 9.50
  • Bid 9.21 x 200
  • Ask 9.27 x 100
  • Day's Range 9.05 - 9.61
  • 52 Week Range 6.30 - 11.92
  • Volume 288,706
  • Avg. Volume 127,085
  • Market Cap (intraday) 250.403M
  • Beta (5Y Monthly) 0.40
  • PE Ratio (TTM) --
  • EPS (TTM) -0.60
  • Earnings Date May 9, 2024 - May 13, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 18.33

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

www.fennecpharma.com

29

Full Time Employees

December 31

Fiscal Year Ends

Recent News: FENC

Performance Overview: FENC

Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

FENC
17.65%
S&P/TSX Composite index
5.03%

1-Year Return

FENC
20.00%
S&P/TSX Composite index
6.37%

3-Year Return

FENC
34.30%
S&P/TSX Composite index
15.66%

5-Year Return

FENC
107.17%
S&P/TSX Composite index
32.78%

Compare To: FENC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: FENC

Valuation Measures

Annual
As of 4/22/2024
  • Market Cap

    252.45M

  • Enterprise Value

    270.14M

  • Trailing P/E

    --

  • Forward P/E

    30.67

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    11.73

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    12.71

  • Enterprise Value/EBITDA

    -21.85

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -75.50%

  • Return on Assets (ttm)

    -29.67%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    21.25M

  • Net Income Avi to Common (ttm)

    -16.05M

  • Diluted EPS (ttm)

    -0.60

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    13.27M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -12.35M

Research Analysis: FENC

Analyst Price Targets

16.00
18.33 Average
9.24 Current
22.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: FENC

Fair Value

9.24 Current
 

Dividend Score

0 Low
FENC
Sector Avg.
100 High
 

Hiring Score

0 Low
FENC
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
FENC
Sector Avg.
100 High
 

People Also Watch